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Abstract
Colorectal cancer is the fourth most common form of cancer worldwide and ranks third among the cancer-related
deaths in the US and other Western countries. It occurs with equal frequency in men and women, constituting 10%
of new cancer cases in men and 11% in women. Despite recent advancement in therapeutics, the survival rates
from metastatic are less than 5%. Growing evidence supports the contention that epithelial cancers including
colorectal cancer, the incidence of which increases with aging, are diseases driven by the pluripotent, self-renewing
cancer stem cells (CSCs). Dysregulation of Wnt, Notch, Hedgehog and/or TGF-β signaling pathways that are
involved in proliferation and maintenance of CSCs leads to the development of CRC. This review focuses on the
signaling pathways relevant for CRC to understand the mechanisms leading to tumor progression and therapy
resistance, which may help in the development of therapeutic strategies for CRC.
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Colorectal cancer, the third most common cancer in
women and the fourth in men, causes 610,000 deaths
per year worldwide [1]. The American Cancer Society
has reported 101,340 new cases of colon and 39,870
cases rectal cancers and 49,380 deaths in 2011 in the
US. The primary cause of death is due to liver metastasis
[2]. Despite recent advances in medicine nearly 50% of
patients with colorectal cancer show tumor recurrence.
Although the reason for this is not fully understood, the
presence of chemotherapy-resistant cancer stem (CSCs)
is thought to be one the primary causes for tumor recurrence [3]. A number of signaling pathways, most notably
Wnt/β-catenin, notch and Hedgehog play important
roles in maintaining the growth and functional integrity
of CSC. Therefore, a better understanding of the signaling mechanisms in CSC will aid in the development of
new therapeutic strategies for CRC.

Stem cell niche in the colon
The colon or large intestine consists of five layers: - the
mucosa, submucosa, muscularis mucosa, muscularis
externa, and serosa. The flat mucosal surface is lined by
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an absorptive and secretory epithelium (simple columnar)
interspersed with deep crypts projecting deep into the
underlying submucosa called crypts of Lieberkuhn. Normal human colon consists of millions of crypts, each containing about 2000 cells. Three main epithelial cell
lineages comprise a crypt: the columnar cells or colonocytes, the mucin-secreting cells or goblet cells, and the
enteroendocrine cells. A fourth category Paneth cell is occasionally present in ascending colon or in certain disease
condition [4]. They play important roles in host defense to
protect stem cells. The adult mammalian intestinal epithelium is unique for its rapidly self renewing property.
Under normal circumstances, turnover of epithelial cell
lineages occurs constantly in every 2–7 days but this
process become faster during tissue repair and wound
healing [5]. The regeneration is maintained by adult stem
cells. According to unitarian theory, proposed in 70s, all
four cell lineages within the gastrointestinal epithelium are
clonal populations derived from a slowly cycling clonogenic stem cells (SC) [6]. The upper one-third of the colonic crypt consists of differentiated cells (colonocytes,
goblet cells, enteroendocrine cells) and lower two-third is
predominantly composed of transit-amplifying cells (TA
cells). Stem cells are located at the bottom of the crypt
and 5-10 stem cells are predicted to be present in each
crypt [7]. At the crypt base, in the vicinity of basal lamina,
stem cells are surrounded by mesenchymal cells that are
of myofibroblast lineage. These pericryptal myofibroblasts

© 2012 Roy and Majumdar; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.

Roy and Majumdar Journal of Molecular Signaling 2012, 7:11
http://www.jmolecularsignaling.com/content/7/1/11

produce the Wnt signalling ligands which bind to Frizzled
receptors as well as morphogenetic protein (BMP) antagonists gremlin 1(GREM1), gremlin 2 (GREM2) on basal
epithelial stem cells and also can modulate notch signaling. They can regulate stem cell functions by modulating
effects of Wnt signalling on ephrin B1 (EFNB1) and its
receptors EPHB2, EPHB3 in the stem cells [4].

Colon cancer stem cells
German pathologist Rudolf Virchow was the first to
propose CSC hypothesis in 1855. He predicted that cancers occur upon activation of dormant embryonic-like
cancerous cells present in mature tissues but not spontaneously [8]. It was Lapidot who, subsequently, proved
the CSC hypothesis in 1994. He demonstrated that
human acute myeloid lymphoma cells, bearing the stem
cell characters, produced leukemia in immune compromised mice [9]. After this discovery, the presence of
CSCs was searched in solid tumors [10]. In 2007 O'Brien
and Vitiani, individually, discovered colon cancer stem
cells. O'Brien et al purified CD133+ human colon
cancer-initiating cell (CC-IC) and transplanted them
into renal capsule of immunodeficient mice. Using limiting dilution analysis they showed 1/5.73 × 104 unfractionated tumor cells produced tumor in immunodeficient
mice while 1/262 of CC-IC in CD133+ cells formed
tumor [11]. Vitiani et al reported that only 2.5% of the
tumorigenic cells in colon cancer had high CD133 expression. Subcutaneous injection of CD133+ colon cancer cells produced tumors in immunodeficient mice,
whereas CD133- cells did not. Serial transplantation of
such tumor in several generations gives rise to tumor
with identical phenotype. These cells can also grow in
serum free media in vitro bearing the same antigenic
character and transplantation ability like the original
tumor [12].
In terms of self-renewal and multipotency for differentiation into a particular type, CSCs are very much
similar to normal adult stem cells. Because of their
scarcity among tumor mass, identification and
characterization of CSC remain a technical challenge.
However, putative stem cell markers are being used to
isolate CSCs. Discussion on stem cell markers is not a
scope of this article, but for the sake of convenience
markers of normal and colon cancer stem cells are
listed Table 1.
To date, therapeutic strategies in the treatment of solid
tumors have been focused on targeting specific cellular
signaling pathway that regulates cell proliferation, apoptosis, and angiogenesis. In the present communication,
we will briefly describe the Wnt/β-catenin, TGF-β,
Notch and Hedgehog signaling pathways that are
believed to regulate CSC functions.
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Wnt signaling
Wnt signaling pathway plays a pivotal role in the regulation of epithelial stem cell self renewal [14,15]. In contrast,
dysregulation of this signaling has been implicated in
many epithelial cancers, including colon carcinogenesis
[16,17]. Wnt signals are either transduced to the canonical
Wnt pathway for cell fate determination or to the noncanonical Wnt pathway for controlling the tissue polarity
and cell movement. Canonical and non-canonical Wnt
pathways are activated by different Wnt ligands for example Wnt1, 2, 3, 3A, 8A, 8B, 10A, 10B are known to induce canonical Wnt pathway, whereas Wnt4, 5A, 5B, 6,
7A, and 7B are needed for non-canonical Wnt pathway
[18,19]. Canonical Wnt signals are transduced through
Frizzled/ LRP5/6 complex to stabilize β-catenin by inhibiting its phosphorylation-dependent degradation and to activate downstream target TCF/LEF to regulate specific
gene expression. The two best-studied Wnt non-canonical
Wnt pathways are the Planar Cell Polarity (PCP) and
Wnt/Calcium Pathways [20].
The function of Wnt signaling in adult tissue homeostasis is best studied in the gut, where a gradient of Wnt signaling activity is required for the compartmentalization.
Wnt signaling components are present throughout the
crypt [21]; while active canonical signals are critical to
maintain stem cells located at the bottom of the crypt.
Blockade of Wnt signaling, either by artificial deletion of
TCF4 or overexpression of the Wnt antagonist Dickkopf-1
(DKK1), results in loss of epithelial cell proliferation and
intestinal tissue structure [22].
Mutation induced inactivation of the APC gene or activating mutations of β-catenin is reported in all CRC
patients [23] which are also the major cause of malignant transformation [24]. The loss of function of Wnt
signaling components are responsible for the pathogenesis of CRC [25]. Mutations result in stabilization of βcatenin and everlasting activation of the Wnt-induced
transcription of a number of cell survival genes, even in
the absence of any extracellular signals.
In spite of the mutations in APC or β-catenin genes
leading to constitutive activation of the Wnt signalling
cascade, most colorectal cancers show cellular heterogeneity of β-catenin indicating a more complex regulation of Wnt signalling. When this heterogeneity was
analysed with a Wnt reporter construct, it is observed
that high Wnt activity functionally designates the colon
cancer stem cell (CSC) population. In adenocarcinomas,
high activity of the Wnt pathway is found in tumor cells
located close to stromal myofibroblasts, signifying that
Wnt activity and cancer stemness could be regulated by
extrinsic signals. For example, myofibroblast-secreted
hepatocyte growth factor activates β-catenin-dependent
transcription and subsequently CSC clonogenicity.
Moreover, myofibroblast-secreted factors also restore the
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Table 1 Markers to identify colonic SCs and colon CSCs [13]
Normal Stem Cell

Colon Cancer Stem Cell

Markers

Cellular Functions

Musahi-1

RNA binding protein

Hes-1

Transcriptional repressor

EphB receptors

Cell surface receptors

Bmi-1

Policomb-repressor protein

Lgr-5

Wnt target gene

ALDH1A1

Enzyme

DCAMKL1

Kinase

CD133

Associated with poor prognosis, low survival, and
distant metastasis in colorectal adenocarcinoma.

CD44

Hyaluronic acid receptor

CD166

Call adhesion molecule

ALDH1A1

Enzyme

ATP binding
cassette protein

Drug transporter, effluxes drugs.

OCT4

POU-domain transcription factor, highly expressed in
embryonic stem (ES) cells.

SOX2

Group B of the Sox family of transcription factor,
involved in development.

c-Myc

Transcription factor, high c-Myc levels blocks cell differentiation
and enhance self-renewal of committed and differentiated cells

B-Integrin (CD29)

Cell adhesion molecule

CSC phenotype in more differentiated tumor cells both
in vitro and in vivo [26].
The non-canonical Wnt signaling is reported to
antagonize β-catenin dependent transcription [27], suggesting an anti-oncogenic effect of non-canonical Wnt
signaling. However, VANGL1, a PCP pathway protein,
has been shown to promote metastasis of colon cancer.
Wnt/β-catenin pathway can also regulate the growth
and maintenance of colonospheres, which are considered to be surrogate tumors. Colon CSCs can form floating spheroids under anchorage-independent conditions
in a serum-free defined media. Studies from this laboratory have demonstrated that, while colonospheres have
reduced membrane bound β-catenin, they exhibit
increased levels of total β-catenin, cyclin-D1 and c-myc
and down regulation of axin-1 and phosphorylated βcatenin [28]. Increased expression of β-catenin is associated with induction of transcriptional activation of
TCF/LEF, which is decreased when β-catenin is silenced
using siRNA [28], This leads to decreased colonosphere
formation [28]. In contrast, upregulation of c-myc, a
down-stream effector of TCF/LEF, greatly enhances the
formation of colonospheres [28].

TGF-β signaling
The TGF-β signaling pathway is one of the most commonly altered pathways in human cancers [29]. This
pathway regulates cell proliferation, differentiation, migration, apoptosis, stem cell maintenance and function.

TGFβ superfamily ligands bind to a type II serine/
threonine kinase receptor, which recruits and phosphorylates type I receptor. The type I receptor in turn phosphorylates receptor-regulated SMADs (R-SMADs) which
can bind the comediator Smads (coSMAD). R-SMAD/
coSMAD complexes accumulate in the nucleus where
they act as transcription factors and participate in the
regulation of target gene expression. To date, eight Smad
proteins have been identified and classified into three
functional classes- (i) receptor-activated Smads (R-Smads):
Smad1, Smad2, Smad3, Smad5, Smad8; (ii) comediator
Smads (coSMAD): Smad4, Smad10; (iii) inhibitory Smads:
Smad6, Smad7. Smad proteins function through adaptor
proteins such as SARA and β2SP and by interacting with
multiple other signal transduction pathways. Downstream
targets of TGF-β signaling are key cell-cyclecheckpoint
genes including CDKN1A (p21), CDKN1B (p27), and
CDKN2B (p15) [30].
In normal intestinal epithelium the tumor suppressor
function of TGF-β includes inhibition of cell proliferation and induction of apoptosis. However, in many CRCs
escape the tumor-suppressor effects of TGF- β, hence
become resistant to TGFβ-induced growth inhibition
[31]. Interestingly TGF- β can switch its own role from a
tumor suppressor to a tumor promoter. TGFβ-induced
proliferative pathways are activated if SMAD signaling is
abrogated. It has been demonstrated that TGFβ activates
PI3K to downregulate PTEN for enhancement of cell
proliferation that is independent of SMAD proteins [32].
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Nearly 80% of CRCs is associated with frameshift mutations of TBR2 which is an outcome of errors prone replication of microsatellite sequences present in TBR2
gene [33]. Mutations in the type I receptor (TBR1),
Smad2, Smad4 have been reported for CRC [34].
Loss of β2SP in combination with loss of Smad4 is
found in advanced and metastatic CRC [35].

Role of Notch signaling in normal and cancerous
colon
Notch signaling, an evolutionarily conserved pathway in
multicellular organisms, regulates cell-fate determination
during development and in stem cells. It mediates juxtacrine signaling among adjacent cells. Notch receptors
are single-pass trans-membrane proteins composed of
functional extracellular (NECD), transmembrane (TM),
and intracellular domains. Interaction between Notch
and its ligands initiates a signaling cascade that regulates
differentiation, proliferation, and apoptosis. The core
elements of the Notch signaling system are the Notch
receptor, DSL ligands (Delta and Serrate/Jagged in Drosophila and vertebrates, Lag2 in C. elegans) and CSL
DNA-binding proteins (CBF1/RBPJ-κ in vertebrates, Su
(H) [Suppressor of hairless] in Drosophila, Lag1 in C.
elegans). Four paralogs of the Notch gene- Notch1, 2, 3
and 4, and five Notch ligands- Jagged1, Jagged2, Delta1,
Delta2 and Delta3, have been identified in vertebrates
[36]. Notch proteins contain extracellular EGF (Epidermal Growth Factor)-like repeats, which interact with the
DSL domain of ligands. Activation of Notch upon ligand
binding is followed by proteolytic cleavage releasing an
intracellular domain of Notch (NICD) from the membrane tether. The NICD contains the RAM23 domain
(RAM), which enhances interaction with CSL protein;
NLS (Nuclear Localization Signals); a CDC10/Ankyrin
repeat domain ANK, which mediates interactions with
CSL and other proteins, and a PEST domain rich in proline, glutamate, serine and threonine residues [37]. Next
the Notch COOH-terminal fragment is cleaved by γsecretase (includes Presenilin and Nicastrin) to release
NICD into the cytoplasm. Upon release, the NICD
translocates to the nucleus and associates with the CSL
[CBF1/RBPJ-κ/ in vertebrates, Su (H) in Drosophila, and
Lag-1 in Caenorhabditis elegans], MAML-1 and p300 ⁄
CBP [38]. These complexes activate the transcription of
the HES-1, -5, -7, HEY-1, -2, and HEYL genes encoding
basic helix–loop–helix ⁄ orange domain transcriptional
repressors [39]. Signal transduction from Notch ligands
to the CSL–NICD–MAML-1 cascade is referred to as
canonical Notch signaling pathway. In a non canonical
pathway NICD can also interact with p50 or c-Rel in the
nucleus to enhance nuclear factor (NF)-κB activity [38].
Unlike Notch2, Notch 1 and Jagged 1 are expressed
abundantly in the proliferative zone located within the
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middle- third of the crypt in normal colon [40]. Jagged2
is expressed uniformly across the entire crypt. Several
reports support the importance of Notch signaling for
the intestinal progenitor compartment. Depletion of
Hes-1 is associated with a significant increase in the
secretory lineage of intestinal epithelial cells [41]. Conditional gut-specific inactivation of CSL leads to complete
loss of proliferating crypt progenitor cells and their ultimate conversion into post-mitotic goblet cells [42]. Expression of NICD in the intestine inhibits differentiation
of crypt progenitor cells thereby increasing undifferentiated transient amplifying cell evident from reciprocal
gain-of-function studies [43].
Notch1 and Hes1 are significantly upregulated in colon
adenocarcinomas [44], but remain normal in differentiated epithelial cells. Activation of Notch signaling is essential for the development of adenomas in ApcMin ⁄ +
mice [42]. Hes1 is reported to suppress the expression of
Kru¨ppel-like factor 4, a transcriptional repressor [45].
KLF4, the zinc finger-containing transcription factor, is
highly expressed in terminally differentiated epithelial
cells of the intestine [46], whose overexpression can inhibit colon cancer cell proliferation [47]. Haploinsufficiency of KLF4 augments the development of intestinal
adenomas in ApcMin ⁄ + mice [48]. Both in adenomas and
carcinomas expression of KLF4 is reduced relative to normal mucosa [49].
Role of notch signaling in colon cancer initiating cells
(CCIC) or colon cancer stem cells has been investigated.
NOTCH signaling is reported to be 10 to 30 fold higher
in CCIC in comparison to commonly used colon cancer
cell lines. Using small-molecule inhibitors and short
hairpin RNA knockdown, it has been demonstrated that
NOTCH prevents CCIC apoptosis through repression of
cell cycle kinase inhibitor p27 and transcription factor
ATOH1. NOTCH is also critical to intrinsic maintenance of CCIC self-renewal and the repression of
secretory cell lineage differentiation genes such as
MUC2 [50].

Hedgehog signaling in colon cancer
The hedgehog signaling is named after the polypeptide
ligand, an intercellular signaling molecule called Hedgehog (Hh) found in Drosophila. It is one of the key regulators of animal development and is present in all
bilaterians [51]. The proliferation, migration, and differentiation of target cells are regulated by Hh signaling in
a spatial, temporal, and concentration dependent manner [52].
In mammals, three Hedgehog homologues are present,
of which Sonic hedgehog (Shh) is the best studied. Hh
ligands binds to the transmembrane receptor Patched
(Ptch) leading to the release of Ptch-mediated repression
of Smo and consequent activation of the downstream
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Figure 1 Histology of coloic crypt (illustration adopted and
modified: courtesy Anderson et al [57] & Simone et al [58]).

signaling cascade that activates Gli family of transcription factors [52].
Emerging data support the existence of a pathologic
Hh signaling happening in a similar manner which
involves the tumor microenvironment [53]. Several
reports from many human tumors have suggested that
Hh signaling regulates cancer stem cells [54]. Hh signaling plays a critical role in the process of metastasis in
solid tumors similar by regulating CSC functions [55].
HH-GLI is essential for the proliferation and survival
of primary human colon carcinoma (CC) of all stages.
HH-GLI is active in CC epithelial cells and affects both
tumor growth and CD133+ cancer stem cells. Interestingly, It is reported that an increase in the levels of expression of HH-GLI signaling components in advanced
and metastatic CCs, and their increased dependence on
HH-GLI pathway activity, as compared with nonmetastatic CCs [56].

Concluding remark
Looking into the future, it is obvious that an important
area of investigation will be colon CSCs and their signaling
pathways. Understanding of the coordinated activity of
these pathways might lead to more effective, early diagnosis of cancer and the development of therapeutic strategies
for colorectal cancer, particularly the recurrence of the
disease where CSCs play a prominent role (Figure 1).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RS carried out review of the literature, wrote the first draft and prepared the
manuscript. MAPN, the principal investigator, was responsible for discussion,
critical evaluation of the review and overall supervision of the final
preparation of the manuscript. Both authors read and approved the final
manuscript.

References
1. American Cancer Society: Colorectal Cancer Facts & Figures. Atlanta, Georgia:
American Cancer Society; 2011–2013.
2. Welch JP, Donaldson GA: The clinical correlation of an autopsy study of
recurrent colorectal cancer. Ann Surg 1979, 189:496–502.
3. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev
Cancer 2005, 5(4):275–284.
4. Humphries A, Wright NA: Colonic crypt organization and Tumorigenesis.
Nat Rev Cancer 2008, 8:415–424.
5. Brittan M, Wright NA: Gastrointestinal stem cells. J Pathol 2002, 197:492–509.
6. Cheng H, Leblond CP: Origin, differentiation and renewal of the four
main epithelial cell types in the mouse small intestine. V. Unitarian
Theory of the origin of the four epithelial cell types. Am J Anat 1974,
141:537–561.
7. Willis ND, Przyborski SA, Hutchison CJ, Wilson RG: Colonic and colorectal
cancer stem cells: progress in the search for putative biomarkers. J Anat
2008, 213:59–65.
8. Virchow R: Editorial. Virchows Arch Pathol Anat Physiol Klin Med 1855, 3:23.
9. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Julio C, Minden M,
Paterson B, Caliguiri MA, Dick JE: A cell initiating human acute myeloid
leukaemia after transplantation into SCID mice. Nature 1994, 367:645–648.
10. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours:
accumulating evidence and unresolved questions. Nat Rev Cancer 2008,
8:755–768.
11. O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell
capable of initiating tumour growth in immunodeficient mice. Nature
2007, 445:106–110.
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De
Maria R: Identification and expansion of human colon-cancer-initiating
cells. Nature 2007, 445(7123):111–115.
13. Sanders MA, Majumdar AP: Colon cancer stem cells: implications in
carcinogenesis. Front Biosci 2011, 16:1651–1662.
14. Brabletz S, Schmalhofer O, Brabletz T: Gastrointestinal stem cells in
development and cancer. J Pathol 2009, 217:307–317.
15. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J,
Clouthier SG, Wicha MS: Regulation of mammary stem/progenitor cells by
PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, 7:e1000121.
16. Kolligs FT, Bommer G, Goke B: Wnt/beta-catenin/tcf signaling: a critical
pathway in gastrointestinal tumorigenesis. Digestion 2002, 66:131–144.
17. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW:
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in
beta-catenin or APC. Science 1997, 275:1787–1790.
18. Staal FJ, Luis TC, Tiemessen MM: WNT signalling in the immune system:
WNT is spreading its wings. Nat Rev Immunol 2008, 8:581–593.
19. Sugimura R, Li L: Noncanonical Wnt signaling in vertebrate development,
stem cells, and diseases. Birth Defects Res C Embryo Today 2010, 90(4):243–256.
20. Komiya Y, Habas R: Wnt signal transduction pathways. Organogenesis
2008, 4:68–75.
21. Gregorieff A, Pinto D, Begthel H, Destree O, Kielman M, Clevers H:
Expression pattern of Wnt signaling components in the adult intestine.
Gastroenterology 2005, 129:626–638.
22. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A,
van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M,
Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H:
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype
on colorectal cancer cells. Cell 2002, 111:241–250.

Roy and Majumdar Journal of Molecular Signaling 2012, 7:11
http://www.jmolecularsignaling.com/content/7/1/11

23. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Miki Y,
Mori T, Nakamura Y: Somatic mutations of the APC gene in colorectal
tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992,
1:229–233.
24. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN,
Vogelstein B, Kinzler KW: APC mutations occur early during colorectal
tumorigenesis. Nature 1992, 359:235–237.
25. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ,
Preisinger AC, Hedge P, McKechnie D, et al: Identification of FAP locus
genes from chromosome 5q21. Science 1991, 253:661–665.
26. Vermeulen L, Melo DSE, Van Der Heijden M, Cameron K, de Jong JH,
Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR,
Kemper K, Richel DJ, Stassi G, Medema JP: Wnt activity defines colon
cancer stem cellsand is regulated by the microenvironment. Nat Cell Biol
2010, 12:468–476.
27. Dejmek J, Dejmek A, Safholm A, Sjolander A, Andersson T: Wnt-5a protein
expression in primary dukes B colon cancers identifies a subgroup of
patients with good prognosis. Cancer Res 2005, 65:9142–9146.
28. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP: The Wnt/beta-catenin
pathway regulates growth and maintenance of colonospheres. Mol
Cancer 2010, 9:212.
29. Massague J, Blain SW, Lo RS: TGFbeta signaling in growth control, cancer,
and heritable disorders. Cell 2000, 103(2):295–309.
30. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL: SARA, a FYVE
domain protein that recruits Smad2 to the TGFbeta receptor. Cell 1998,
95(6):779–791.
31. Hoosein NM, McKnight MK, Levine AE, Mulder KM, Childress KE, Brattain DE,
Brattain MG: Differential sensitivity of subclasses of human colon
carcinoma cell lines to the growth inhibitory effects of transforming
growth factor-beta 1. Exp Cell Res 1989, 181(2):442–453.
32. Grady WM, Carethers JM: Genomic and epigenetic instability in colorectal
cancer pathogenesis. Gastroenterology 2008, 135(4):1079–1099.
33. Ilyas M, Efstathiou JA, Straub J, Kim HC, Bodmer WF: Transforming growth
factor beta stimulation of colorectal cancer cell lines: type II receptor
bypass and changes in adhesion molecule expression. Proc Natl Acad Sci
U S A 1999, 96(6):3087–3091.
34. Xu Y, Pasche B: TGF-beta signaling alterations and susceptibility to
colorectal cancer. Hum Mol Genet 2007, 16(spec. no. 1):R14–R20.
35. Tang Y, Katuri V, Srinivasan R, Fogt F, Redman R, Anand G, Said A, Fishbein
T, Zasloff M, Reddy EP, Mishra B, Mishra L: Transforming growth factorbeta suppresses nonmetastatic colon cancer through Smad4 and
adaptor protein ELF at an early stage of tumorigenesis. Cancer Res 2005,
65(10):4228–4237.
36. Ohishi K, Varnum-Finney B, Flowers D, Anasetti C, Myerson D, Bernstein ID:
Monocytes express high amounts of Notch and undergo cytokine
specific apoptosis following interaction with the Notch ligand, Delta-1.
Blood 2000, 95(9):2847–2854.
37. Kopan R: Notch: a membrane-bound transcription factor. J Cell Sci 2002,
115(Pt 6):1095–1097.
38. Shin HM, Minter LM, Cho OH, Gottipati S, Fauq AH, Golde TE, Sonenshein
GE, Osborne BA: Notch1 augments NF-kappaB activity by facilitating its
nuclear retention. EMBO J 2006, 25:129–138.
39. Katoh M: Notch signaling in gastrointestinal tract. Int J Oncol 2007,
30:247–251.
40. Sander GR, Powell BC: Expression of notch receptors and ligands in the
adult gut. J Histochem Cytochem 2004, 52:509–516.
41. Jensen J, Pedersen EE, Galante P, Hald J, Heller RS, Ishibashi M, Kageyama R,
Guillemot F, Serup P, Madsen OD: Control of endodermal endocrine
development by Hes-1. Nat Genet 2000, 24:36–44.
42. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H,
Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H: Notch ⁄ gammasecretase inhibition turns proliferative cells in intestinal crypts and
adenomas into goblet cells. Nature 2005, 435:959–963.
43. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S:
Notch signals control the fate of immature progenitor cells in the
intestine. Nature 2005, 435:964–968.
44. Reedijk M, Odorcic S, Zhang H, Chetty R, Tennert C, Dickson BC, Lockwood
G, Gallinger S, Egan SE: Activation of Notch signaling in human colon
adenocarcinoma. Int J Oncol 2008, 33:1223–1229.

Page 6 of 6

45. Ghaleb AM, Aggarwal G, Bialkowska AB, Nandan MO, Yang VW: Notch
inhibits expression of the Kru¨ppel-like factor 4 tumor suppressor in the
intestinal epithelium. Mol Cancer Res 2008, 6:1920–1927.
46. Shields JM, Christy RJ, Yang VW: Identification and characterization of a
gene encoding a gut-enriched KrA?ppel-like factor expressed during
growth arrest. J Biol Chem 1996, 271:20009–20017.
47. Chen X, Johns DC, Geiman DE, Geiman DE, Marban E, Dang DT, Hamlin G,
Sun R, Yang VW: KrA?ppel-like factor 4 (gut-enriched KrA?ppel-like factor)
inhibits cell proliferation by blocking G1⁄S progression of the cell cycle.
J Biol Chem 2001, 276:30423–30428.
48. Ghaleb AM, McConnell BB, Nandan MO, Katz JP, Kaestner KH, Yang VW:
Haploinsufficiency of Kru¨ppel-like factor 4 promotes adenomatous
polyposis coli dependent intestinal tumorigenesis. Cancer Res 2007,
67:7147–7154.
49. Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW:
Identification of Kru¨ppel-like factor 4 as a potential tumor suppressor
gene in colorectal cancer. Oncogene 2004, 23:395–402.
50. Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML,
Lipkin SM: NOTCH signaling is required for formation and self-renewal of
tumor-initiating cells and for repression of secretory cell differentiation
in colon cancer. Cancer Res 2010, 70:1469–1478.
51. Ingham PW, Nakano Y, Seger C: Mechanisms and functions of Hedgehog
signalling across the metazoa. Nat Rev Genet 2011, 12(6):393–406.
52. Varjosalo M, Taipale J: Hedgehog: functions and mechanisms. Genes Dev
2008, 22:2454–2472.
53. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, Marshall D, Fu L,
Januario T, Kallop D, Nannini-Pepe M, Kotkow K, Marsters JC, Rubin LL, de
Sauvage FJ: A paracrine requirement forHedgehog signalling in cancer.
Nature 2008, 455:406–410.
54. Feldmann G, Dhara S, Fendrich V, et al: Blockade of hedgehog signaling
inhibits pancreatic cancer invasion and metastases: a new paradigm for
combination therapy in solid cancers. Cancer Res 2007, 67:2187–2196.
55. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M,
Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J,
Weinberg RA: The epithelial-mesenchymaltransition generates cells with
properties of stem cells. Cell 2008, 133:704–715.
56. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A:
Human colon cancer epithelial cells harbour active HEDGEHOG-GLI
signalling that is essential for tumour growth, recurrence, metastasis and
stem cell survival and expansion. EMBO Mol Med 2009, 1:338–351.
57. Anderson EC, Hessman C, Levin TG, Monroe MM, Wong MH: The Role of
Colorectal Cancer Stem Cells in Metastatic Disease and Therapeutic
Response. Cancers (Basel) 2011, 3(1):319–339.
58. Simone DFS, Mancuso P, Benfante A, Spina M, Iovino I, Dieli F, Giorgio S,
Todaro M: Colon Cancer Stem Cells: Bench-to-Bedside—New
Therapeutical Approaches in Clinical Oncology for Disease Breakdown.
Cancers 2011, 3(2):1957–1974.
doi:10.1186/1750-2187-7-11
Cite this article as: Roy and Majumdar: Signaling in colon cancer stem
cells. Journal of Molecular Signaling 2012 7:11.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

